Opioids in Medicine

A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States

By

Enno Freye

*Heinrich-Heine-University, Düsseldorf, Germany*

In collaboration with

Joseph Victor Levy

*University of the Pacific, Webster Street, San Francisco/California, USA*
Contents

Introduction xi

Part I  Rational for the Use of Opioids in Nociceptive Transmission

The Nociceptive System, an Elementary Part of the Body's Protective Scheme . 1
Acute Pain – Sequence of Changes in the Body . 3
Differences in Pain Quality . 5
Anatomy of Pain and Analgesia . 7
Significance of C-Fibers in Pain Transmission . 8
Significance of Aβ-Fibers in Pain Modulation . 9
Transmission of Pain with Different Qualities . 9
Substance P, a Mediator of Pain and a Member of the Tachykinine Family . 11
Supraspinal Processing of Pain . 13
Transduction of Nociception Via the Spinothalamic Tracts . 17
The Descending Antinociceptive System . 18
Neurophysiology of Pain – Type of Receptor Sites Involved in Therapy . 23
Transduction of Nociceptive Afferences Via Ascending Pathways . 24
Different Therapeutic Approaches in Pain Therapy . 24
Significance of Bradykinins in Inflammatory Pain . 25
Cox Inhibitors in the Alleviation of Pain . 26
The Opioid Receptor System – Main Target in Pain Therapy . 27
Inhibitory and Excitatory Effects of Nociception at the Spinal Cord Level . 28
Neurohormones In Transmission of Nociception . 29
Melanocortins . 29
Cholecystokins . 29
Calcitonin-Gene-Related Neuropeptide . 30
Galanin . 30
Nitric Monoxide, Mediator for Chronic Pain . 31
The Cannabinoid System . 32
Ion Channel Modulators Resulting in Facilitation/Inhibition of Nociception . 32
The P2X and P2Y Receptor System . 32
The Vanilloid Receptor System . 33
Voltage-Gated Sodium Channels as Ion Conduit Modulators . 34
Contents

Difference in Sedative-Hypnotic Effect of Opioids ........................................ 142
Difference in the Hypnosedative and Analgesic Effect of Potent Opioids .......... 144
Potential Epileptogenic Potency of Opioids ...................................................... 149
The Antitussive Action of Opioids (Blockade of Cough Reflex) ....................... 150
Dependence Liability of Opioids – Pharmacological Principles of Addiction ...... 154
Neurobiological Changes with Addiction ............................................................ 158
Opioids Inducing Nausea and Emesis ................................................................. 158
Opioids and Muscular Rigidity .............................................................................. 166
The Pupillary Effect of Opioids .......................................................................... 168
Opioids and Gastrointestinal Inhibition (Constipation) ...................................... 170
Clinical Relevance of Opioid-Induced Constipation .......................................... 172
Opioids and the Cardiovascular System ............................................................... 172
References ............................................................................................................. 178

Part III Opioids, an Integrative Part in Perioperative Medicine

Intraoperative Use of Opioids for Anesthesia ..................................................... 189
Potentiation of Opioid-Based Anesthesia ............................................................ 199
Pharmacokinetics of Opioids: Significance for Clinical Use in Anesthesia ....... 206
Significance of Pharmacokinetic Data for Practical Use .................................... 216
Advantages of “Maintenance Phase” Infusions Compared to Intermittent Bolus Dose ........................................................................................................ 218
Use of Target Controlled Infusion (TCI) Systems in Anesthesia ....................... 220
“On-Top”-Dose of Either Alfentanil or Remifentanil in an Opioid-Based Anesthetic Regimen ............................................................ 224
Recommendations for the Use of Remifentanil ................................................. 233
The Pharmacology of Sufentanil ........................................................................... 236
Respiratory Depression After Sufentanil ............................................................. 238
The Hypnosedative Effect of Sufentanil ............................................................. 240
Sufentanil and Muscular Rigidity ......................................................................... 240
Sufentanil in Selective Operations ....................................................................... 241
Neurosurgery ......................................................................................................... 241
Sufentanil in Open-Heart Surgery ....................................................................... 243
Interaction of Sufentanil ....................................................................................... 245
Volatile Aspects ..................................................................................................... 245
Muscle Relaxants .................................................................................................. 245
Barbiturates ............................................................................................................ 247
Practical Considerations for the Use of Sufentanil .............................................. 248
Examples for the Use of Sufentanil in Anesthesia .............................................. 251
Opioids for Use in Postoperative Pain Management ........................................... 252
Addiction Liability by Use of Opioids for Postoperative Pain ......................... 255
Time-Contingent Dosing of Opioids for Postoperative Pain .............................. 255
Selection of the Appropriate Agent in Postoperative Pain Management ............ 256
Choice of Opioid Agents for Post-Operative Pain Treatment ............................. 260
Dosage of Opioid Analgesics in Post-Operative Pain Treatment ....................... 262
Implications of Agonist/Antagonists in Postoperative Pain Management .......... 267
Patient-Controlled Analgesia (PCA) for Postoperative Pain Therapy .......... 270
Opioids On-Demand, Without Use of a PCA System .... 274
New Techniques for Postoperative Pain Management .... 276
Selective Opioid Antagonists for Postoperative Reversal of Opioid Side Effects .... 277
Postoperative Opioids - Summary and Outlook .... 282
Neuraxial Administration of Opioids for Pain Therapy .... 283
Side Effects of Epidural Opioids .... 287
Lipophilic or Hydrophilic Opioids for Neuraxial Use .... 291
Extended-Release Epidural Morphine for Postoperative Pain .... 294
Combination of an Epidural Opioid with a Local Anesthetic .... 297
Continuous-Infusion Epidural Analgesia (CIEA) .... 298
Intrathecal Use of Opioids .... 299
Mixed Agonist/Antagonists and α2-Agonists for Neuraxial Use .... 301
References .... 302

Part IV Use of Potent Opioids for Chronic Pain Management Long-Term Management of Chronic Pain .... 318
Defining the Different Type of Opioids .... 321
Agonists .... 321
Antagonists .... 321
Mixed Agonist-Antagonists .... 321
The WHO Guidelines for Pain Therapy .... 322
Dosing of Opioids in Tumor Pain .... 324
Co-Analgesics (Adjuvants) for Long-Term Pain Therapy with Opioids .... 330
Buprenorphine - Opioid with Unique Receptor Kinetics for Chronic Pain .... 334
Transdermal Patches for Use in Chronic Pain - Fentanyl TTS and Buprenorphine TDS .... 341
Rational for the Use of Transdermal Systems .... 341
Pharmacokinetics of Opioids Used in Transdermal Systems .... 343
Specificity of Transdermal Buprenorphine .... 344
Oral Transmucosal Fentanyl Citrate (OTFC) Stick for Treatment of Breakthrough Pain .... 347
Differences in Transdermal Technology and Pharmacology of Fentanyl and Buprenorphine .... 351
Change from Oral Morphine to a Transdermal Opioid .... 354
Rotation from Oral Morphine to Transdermal Buprenorphine .... 355
Commonly Observed Side-Effects in Long-Term Pain Treatment with Opioids .... 357
Respiratory Depression .... 357
Development of Dependency in Chronic Opioid Use .... 358
Development of Tolerance During Long-Term Use of Opioids .... 361
Constipation, a Common Side Effect of Opioids .... 364
Nausea and Vomiting .... 365
Marked Sedation .... 366
Pruritus .... 366
Rotation from One Opioid to Another .... 366
Part V Detection of Illicit Use of Opioids in Primary Care

Introduction 412
Physical Dependency 414
Definitions and Concepts in Physical Dependency 416
Terminology in Illicit Use of Opioids 418
Bioavailability of Pain Medicine Related to Abuse 419
Avoiding Abuse Liability When Prescribing Opioids 420
Avoiding Illicit Use by Ongoing Assessment and Documentation 422
Typical Drug Scams to Obtain a Prescription Opioid 423
Prescribing Opioids – The Controlled Substances Act from 1979 423
Typical Patterns as Predictive Signs of Aberrant Drug-Related Behavior 426
Avoiding Drug Diversion from Medical to Illicit Use 427
Avoiding Illicit Use by Combining Opioids with Antidepressants/Antiepileptics 428
Demask the Patient Prone to Develop Illicit Use 429
Further Stigma of Persons with a Potential Drug Addictive Behavior Pattern 430
The Alcohol Addictive Patient 431
The Most Common Signs of Alcohol Addiction 433
Concomitant Sequelae of Alcoholism 434
Common Comprehensions on Prescription Drug Abuse 434
Physical Signs and Symptoms of Hard Drug Abuse 435
The Red Flags During Initial Assessment 439
Use of Urine Drug Screening (UDS) 441